Skip to main content

Table 1 Patient characteristics

From: Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease

 

UC

CD

N

15

25

Gender (n)

  

   Female

4

11

   Male

11

14

Age median (range)

25 (16-57)

33 (18-51)

Disease duration (y) (median, range)

1-40 (10,7)

1-25 (9,6)

Smokers

0

0

Disease severity (UCDAI, HB) (n)

  

   Mild

1

 

   Moderate

13

 

   Severe

  

   >5 in HB (range)

 

24 (5-27)

Previous medication (n)

  

   Aminosalicylates

15

25

   Glucocorticosteroids

15

25

   Immunomodulators (6-MP/AZA)

15

25

   Infliximab

 

9

   Antibiotics

12

23

Patients with extraintestinal manifestations (n)

4

12

Patients with previous abdominal surgery for IBD (n)

4

6

Patients with perianal fistulas (n)

 

5

Disease location

  

   Extensive

6

 

   Left side

7

 

   Proctitis

2

 

   Extensive colonic

 

21

   Small bowel + colonic

 

1

   Esofagus + small bowel

 

1

   Stomach + small bowel + colonic

 

1

  1. UCDAI score of 3 to 6 is defined as mild, 7 to 10 as moderate and 11 to 12 as severe UC.
  2. HB score ≥ 5 defined as active CD